Kerry A Rogers, MD
Academic Title: Associate Professor in the College of Medicine
Research Program: Leukemia and Hematologic Malignancies
About Me
More info forI am a hematologist-oncologist dedicated to advancing the care and treatment of patients with chronic lymphocytic leukemia (CLL) and autoimmune cytopenias. Following my initial medical education at Chicago Medical School, I completed my residency in internal medicine at the University of Michigan. I then undertook fellowship here at The Ohio State University in hematology and oncology, and after completion of my training, I was delighted to join the staff at the OSUCCC – James. In addition to clinical work, I spend time teaching our medical students and resident physicians as an assistant professor in the Department of Hematology. As a member of the Leukemia and Hematologic Malignancies Program at the OSUCCC – James, I conduct research in the Experimental Hematology Laboratory developing novel therapeutics for autoimmune cytopenias. My research group has an interest in finding optimal strategies for the use of BTK inhibitors, including studying resistance, combination therapies and treatment discontinuation. I am currently the principal investigator on four open and two pending clinical trials in this area, including two investigator-sponsored trials and a NCI study. I have also written several articles for publication in such medical journals as Leukemia and Cancer Cell, and have prepared numerous abstracts and posters for presentations. What I love most about The James is working with very passionate and committed team members to give our patients the very best care. I feel that communication is a key aspect to providing the best medical care and enjoy spending time with my patients most of all.
Clinical Expertise
More info for- Hemophilia A
- Hairy Cell Leukemia
- Chronic Lymphocytic Leukemias
- von Willebrand Diseases
- Hemophilia B
- Blood Cancers
Research Interests
More info for- Hematologic Neoplasms
- Leukemia, Hairy Cell
- Leukemia, Lymphocytic, Chronic, B-Cell
Where I See Patients
More info forEducation & Training
More info forFellowship - Hematology & Oncology
- Ohio State University Wexner Medical Center
700 Ackerman Rd, Columbus, OH
Medical School
- Rosalind Franklin University of Medicine/Science
3333 Green Bay Rd, North Chicago, IL
Internship - Internal Medicine
- University of Michigan Medical Center
1500 E Medical Center Dr, Ann Arbor, MI
Residency - Internal Medicine
- University of Michigan Medical Center
1500 E Medical Center Dr, Ann Arbor, MI
- Ohio State University Wexner Medical Center
Academic Office & Contact Information
More info forAcademic Office:
Comprehensive Cancer Center 0458
410 W 12th Ave
Columbus, Ohio 43210-1214Email:
rogers.924@osu.eduReviews
More info forPatient Satisfaction Review
The overall patient satisfaction rating is an average of all patient responses to the five questions gathered from the Outpatient Oncology survey, developed by Press Ganey Associates for use in oncology clinics across the country. On behalf of The James, Press Ganey administers the survey to patients who see our providers in an outpatient clinic office. For additional information about the patient satisfaction survey, please visit our
Patient Satisfaction Survey page The comments are submitted by patients and reflect their view and opinions. The comments are not endorsed by and do not necessarily reflect the views of The James.
Videos
More info forPublications
More info forOctober 1, 2024Incidence, description, and timing of serious and opportunistic infections in patients with hairy cell leukemia.
Kapoor N, Zhao Q, Stiff A, Bhat SA, Anghelina MI, Andritsos LA, Blachly JS, Epperla N, Boghdadly ZE, Grever MR, Rogers KA
EJHaem
August 17, 2024Atrial fibrillation burden and clinical outcomes following BTK inhibitor initiation.
Gambril JA, Ghazi SM, Sansoterra S, Ferdousi M, Kola-Kehinde O, Ruz P, Kittai AS, Rogers K, Grever M, Bhat S, Wiczer T, Byrd JC, Woyach J, Addison D
Leukemia
August 8, 2024LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclax-resistant chronic lymphocytic leukemia.
Ravikrishnan J, Diaz-Rohena DY, Muhowski E, Mo X, Lai TH, Misra S, Williams CD, Sanchez J, Mitchell A, Satpati S, Perry E, Kaufman T, Liu C, Lozanski A, Lozanski G, Rogers K, Kittai AS, Bhat SA, Collins MC, Davids MS, Jain N, Wierda WG, Lapalombella R, Byrd JC, Tan F, Chen Y, Chen Y, Shen Y, Anthony SP, Woyach JA, Sampath D
Haematologica
June 8, 2024Hairy cell leukemia variant and WHO classification correspondence Re: 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms.
Grever M, Andritsos L, Anghelina M, Arons E, Banerji V, Barrientos J, Bhat SA, Blachly J, Broccoli A, Call T, Dearden C, Dietrich S, Else M, Epperla N, Fagarasanu A, Falini B, Forconi F, Gozzetti A, Hampel P, Hermel DJ, Iyengar S, Johnston JB, Juliusson G, Kreitman RJ, Lauria F, Lozanski G, Oakes CC, Parikh SA, Park J, Quest G, Rai K, Ravandi F, Robak T, Rogers KA, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam CS, Tiacci E, Troussard X, Wörmann B, Zent CS, Zenz T, Zinzani PL
Leukemia
June 1, 2024GAIA/CLL13 provides further insight on venetoclax use in chronic lymphocytic leukaemia.
Rogers KA
Lancet Oncol
March 29, 2024Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study.
Kittai AS, Bond D, Huang Y, Bhat SA, Blyth E, Byrd JC, Chavez JC, Davids MS, Dela Cruz JP, Dowling MR, Duffy C, Ho C, Jacobson C, Jaglowski S, Jain N, Lin KH, Miller C, McCarthy C, Omer Z, Parry E, Rai M, Rogers KA, Saha A, Schachter L, Scott H, Senapati J, Shadman M, Siddiqi T, Stephens DM, Vanguru V, Wierda W, Woyach JA, Thompson PA
J Clin Oncol
March 27, 2024A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia.
Hampel PJ, Swaminathan M, Rogers KA, Parry EM, Burger JA, Davids MS, Ding W, Ferrajoli A, Hyak JM, Jain N, Kenderian SS, Wang Y, Wierda WG, Woyach JA, Parikh SA, Thompson PA
Blood Adv
March 18, 2024Pairing obinutuzumab with venetoclax in relapsed CLL.
Rogers KA, Thompson PA
Leuk Lymphoma
February 19, 2024Comparison of karyotype scoring guidelines for evaluating karyotype complexity in chronic lymphocytic leukemia.
Avenarius MR, Huang Y, Kittai AS, Bhat SA, Rogers KA, Grever MR, Woyach JA, Miller CR
Leukemia
February 15, 2024Racial disparities in chronic lymphocytic leukemia/small lymphocytic lymphoma accounting for small molecule inhibitors: A real-world cohort analysis.
Kittai AS, Hang Y, Bhat SA, Clark A, Grever M, Rhodes JM, Roberts M, Rogers KA, Teschemaker A, Munoz-Sagastibelza M, Woyach JA, Barrientos JC
Am J Hematol
January 12, 2024Long-term Follow-up from A041202 Shows Continued Efficacy of Ibrutinib Regimens for Older Adults with CLL.
Woyach JA, Perez Burbano GE, Ruppert AS, Miller CR, Heerema NA, Zhao W, Wall A, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Stephens DM, Brown JR, Lozanski G, Blachly JS, Nattam S, Larson RA, Erba HP, Litzow MR, Luger SM, Owen C, Kuzma C, Abramson JS, Little RF, Dinner SN, Stone RM, Uy GL, Stock W, Mandrekar SJ, Byrd JC
Blood
November 1, 2023Single-center study of outcomes of patients with hairy cell leukemia who contracted SARS-CoV-2.
Annunzio K, Ozga M, Huang Y, Anghelina M, Bhat SA, Blachly JS, Grever MR, Lozanski G, Neal J, Shindiapina P, Rogers KA
EJHaem
October 18, 2023Characteristics and Outcomes of Patients with CLL and CDKN2A/B Deletion by Fluorescence in situ Hybridization.
Teierle SM, Huang Y, Kittai AS, Bhat SA, Grever MR, Rogers KA, Zhao W, Jones D, Byrd JC, Avenarius MR, Heerema NA, Woyach JA, Miller CR
Blood Adv
October 1, 2023Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia: JACC: CardioOncology State-of-the-Art Review.
Quartermaine C, Ghazi SM, Yasin A, Awan FT, Fradley M, Wiczer T, Kalathoor S, Ferdousi M, Krishan S, Habib A, Shaaban A, Kola-Kehinde O, Kittai AS, Rogers KA, Grever M, Ruz P, Bhat S, Dickerson T, Byrd JC, Woyach J, Addison D
JACC CardioOncol
August 2, 2023Real-world time to discontinuation of first-line venetoclax + obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma.
Lu X, Emond B, Qureshi ZP, Wu PH, Forbes SP, Hilts A, Liu S, Lafeuille MH, Lefebvre P, Huang Q, Rogers KA
Curr Med Res Opin
July 1, 2023Correction: Evaluation of bleeding events in patients receiving acalabrutinib therapy.
Kumar PS, Wiczer T, Rosen L, Pollauf AJ, Zheng A, Palettas M, Azali L, Bhat SA, Byrd JC, Grever MR, Rogers KA, Woyach JA, Kittai AS
Leukemia
April 3, 2023Refining prognosis in chronic lymphocytic leukemia with normal Fluorescence in situ hybridization results.
Avenarius MR, Huang Y, Hyak J, Byrd JC, Bhat SA, Grever M, Kittai AS, Rogers KA, Jones D, Zhao W, Heerema NA, Abruzzo LV, Woyach J, Miller CR
Hematol Oncol
March 17, 2023Evaluation of bleeding events in patients receiving acalabrutinib therapy.
Kumar PS, Wiczer T, Rosen L, Pollauf AJ, Zheng A, Palettas M, Azali L, Bhat SA, Byrd JC, Grever MR, Rogers KA, Woyach JA, Kittai AS
Leukemia
February 2, 2023Cardiovascular Magnetic Resonance Imaging in Patients With Ibrutinib-Associated Cardiotoxicity.
Buck B, Chum AP, Patel M, Carter R, Nawaz H, Yildiz V, Ruz P, Wiczer T, Rogers KA, Awan FT, Bhat S, Guha A, Kittai AS, Simonetti OP, Raman SV, Wallace G, Sanchez R, Bonsu JM, Gambril J, Haddad D, Mann J, Wei L, Kola-Kehinde O, Byrd JC, Woyach JA, Addison D
JAMA Oncol
December 14, 2022Diminished Humoral and Cellular Responses to SARS-CoV-2 Vaccines in Patients with Chronic Lymphocytic Leukemia.
Ujjani CS, Gooley TA, Spurgeon SE, Stephens DM, Lai C, Broome CM, O'Brien SM, Zhu H, Laing KJ, Winter AM, Pongas G, Greninger AL, Koelle DM, Siddiqi T, Davids MS, Rogers KA, Danilov AV, Sperling AL, Tu B, Sorensen T, Launchbury KM, Burrow CJ, Quezada G, Hill JA, Shadman M, Thompson PA
Blood Adv
December 13, 2022Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia.
Ravandi F, Kreitman RJ, Tiacci E, Andritsos L, Banerji V, Barrientos JC, Bhat SA, Blachly JS, Broccoli A, Call T, Chihara D, Dearden C, Demeter J, Dietrich S, Else M, Epperla N, Falini B, Forconi F, Gladstone DE, Gozzetti A, Iyengar S, Johnston JB, Jorgensen J, Juliusson G, Lauria F, Lozanski G, Parikh SA, Park JH, Polliack A, Quest G, Robak T, Rogers KA, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam CS, Thompson PA, Troussard X, Zent CS, Zenz T, Zinzani PL, Wörmann B, Rai K, Grever M
Blood Cancer J
November 15, 2022Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia.
Muhowski EM, Ravikrishnan J, Gordon B, Yu L, Misra S, Walker B, Eathiraj S, Sampath D, Rogers KA, Byrd JC, Woyach JA
J Hematol Oncol
October 10, 2022Patient characteristics that predict Richter's Transformation in patients with CLL treated with ibrutinib.
Kittai AS, Huang Y, Beckwith KA, Bhat SA, Bond DA, Byrd JC, Goldstein D, Grever MR, Miller C, Rogers KA, Yano M, Woyach JA
Am J Hematol
September 7, 2022Development of a distributed international patient data registry for hairy cell leukemia.
Andritsos LA, Anghelina M, Neal J, Blachly JS, Mathur P, Lele O, Dearden C, Iyengar S, Cross M, Zent CS, Rogers KA, Epperla N, Lozanski G, Oakes CC, Kraut E, Ruppert AS, Zhao Q, Bhat SA, Forconi F, Banerji V, Handunnetti S, Tam CS, Seymour JF, Else M, Kreitman RJ, Saven A, Call T, Parikh SA, Ravandi F, Johnston JB, Tiacci E, Troussard X, Tallman MS, Dietrich S, Tadmor T, Gozzetti A, Zinzani PL, Robak T, Quest G, Demeter J, Rai K, Fernandez SA, Grever M
Leuk Lymphoma
September 2, 2022Corrigendum to "Patient-driven research: Initial results from a prospective health-related quality of life study performed at the request of patients living with hairy cell leukemia" [Leuk. Res. 120 (2022) 106919].
Anghelina M, Naughton MJ, Zhao Q, Ruppert AS, Neal J, Rogers KA, Blachly JS, Lozanski G, Bhat SA, Kraut E, Epperla N, Mathur P, Zent CS, Banerji V, Dearden C, Hutchinson T, Grever M, Andritsos LA
Leuk Res
September 1, 2022Patient-driven research: Initial results from a prospective health-related quality of life study performed at the request of patients living with hairy cell leukemia.
Anghelina M, Naughton MJ, Zhao Q, Ruppert AS, Neal J, Rogers KA, Blachly JS, Lozanski G, Bhat SA, Kraut E, Epperla N, Mathur P, Zent CS, Banerji V, Dearden C, Hutchinson T, Grever M, Andritsos LA
Leuk Res
August 2, 2022Ventricular Arrhythmias and Sudden Death Events following Acalabrutinib initiation.
Bhat SA, Gambril JA, Azali L, Chen ST, Rosen L, Palettas M, Wiczer T, Kalathoor S, Zhao Q, Rogers KA, Kittai AS, Grever MR, Awan FT, Ruz P, Byrd JC, Woyach JA, Addison D
Blood
July 14, 2022Combined BCL2 and BTK Inhibition in CLL Demonstrates Efficacy after Monotherapy with Both Classes.
Hyak JM, Huang Y, Rogers KA, Bhat SA, Grever MR, Byrd JC, Kittai AS, Jones D, Miller CR, Woyach JA
Blood Adv
July 14, 2022Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation.
Chen ST, Azali L, Rosen L, Zhao Q, Wiczer T, Palettas M, Gambril J, Kola-Kehinde O, Ruz P, Kalathoor S, Rogers K, Kittai A, Grever M, Awan F, Byrd JC, Woyach J, Bhat SA, Addison D
J Hematol Oncol
July 11, 2022Clinical and economic burden of tumor lysis syndrome among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: A real-world US retrospective study.
Rogers KA, Lu X, Emond B, Côté-Sergent A, Kinkead F, Lafeuille MH, Lefebvre P, Huang Q
J Manag Care Spec Pharm
June 27, 2022Differential regulation of CTLA4 expression through BTK-dependent and independent mechanisms in CLL.
Yano M, Nunes J, Mo XM, Rogers KA, Woyach JA, Byrd JC, Muthusamy N
Blood Adv
May 24, 2022Selinexor combined with ibrutinib demonstrates tolerability and safety in advanced B-cell malignancies: A phase I study.
Stephens DM, Huang Y, Ruppert AS, Walker JS, Canfield D, Cempre CB, Fu Q, Baker S, Hu B, Shah H, Vadeboncoeur R, Rogers KA, Bhat S, Jaglowski SM, Lockman H, Lapalombella R, Byrd JC, Woyach JA
Clin Cancer Res
April 29, 2022Evaluation of allogeneic and autologous membrane-bound IL-21-expanded NK cells for chronic lymphocytic leukemia therapy.
Yano M, Sharpe C, Lance JR, Ravikrishnan J, Zapolnik K, Mo XM, Woyach JA, Sampath D, Kittai AS, Vasu S, Bhat SA, Rogers KA, Lee D, Muthusamy N, Byrd JC
Blood Adv
April 27, 2022Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib and acalabrutinib treated patients.
Black GS, Huang X, Qiao Y, Tarapcsak S, Rogers KA, Misra S, Byrd JC, Marth GT, Stephens DM, Woyach JA
Blood
February 28, 2022Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma.
Siddiqi T, Coutre S, McKinney M, Barr PM, Rogers K, Mokatrin A, Valentino R, Szoke A, Deshpande S, Zhu A, Arango-Hisijara I, Osei-Bonsu K, Wang M, O'Brien S
Leuk Lymphoma
February 18, 2022Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open-label study.
Kuter DJ, Rogers KA, Boxer MA, Choi M, Agajanian R, Arnold D, Broome CM, Field JJ, Murakhovskaya I, Numerof R, Tong S
Am J Hematol
November 17, 2021Venetoclax plus Dose-Adjusted R-EPOCH (VR-EPOCH) for Richter's Syndrome.
Davids MS, Rogers KA, Tyekucheva S, Wang Z, Pazienza S, Renner SK, Montegaard J, Ihuoma UO, Lehmberg TZ, Parry EM, Wu CJ, Jacobson CA, Fisher DC, Thompson PA, Brown JR
Blood
November 17, 2021Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past is Prologue" (Shakespeare).
Mato AR, Davids MS, Sharman J, Roeker LE, Kay N, Kater A, Rogers K, Thompson MC, Rhodes J, Goy A, Skarbnik A, Schuster SJ, Tam CS, Eyre TA, O'Brien S, Nabhan C, Lamanna N, Sun C, Shadman M, Pagel JM, Ujjani C, Brander D, Coombs CC, Jain N, Cheah CY, Brown JR, Seymour JF, Woyach JA
Clin Cancer Res
August 9, 2021Optimizing extracellular vesicles' isolation from chronic lymphocytic leukemia patient plasma and cell line supernatant.
Elgamal S, Cocucci E, Sass EJ, Mo XM, Blissett AR, Calomeni EP, Rogers KA, Woyach JA, Bhat SA, Muthusamy N, Johnson AJ, Larkin KT, Byrd JC
JCI Insight
July 27, 2021The impact of increasing karyotypic complexity and evolution on survival in CLL patients treated with ibrutinib.
Kittai AS, Miller CR, Goldstein D, Huang Y, Abruzzo LV, Beckwith KA, Bhat S, Bond DA, Grever MR, Heerema NA, Rogers KA, Ruppert AS, Byrd JC, Woyach JA
Blood
July 23, 2021COVID-19 in patients with CLL: improved survival outcomes and update on management strategies.
Roeker LE, Eyre TA, Thompson MC, Lamanna N, Coltoff A, Davids MS, Baker P, Leslie LA, Rogers KA, Allan JN, Cordoba R, Lopez-Garcia A, Antic D, Pagel JM, Martinez-Calle N, Garcia-Marco JA, Hernández-Rivas JÁ, Miras F, Coombs CC, Österborg A, Seddon AN, López-Jiménez J, Wilson MR, El-Sharkawi D, Wojenski D, Ma S, Munir T, Valenciano S, Seymour E, Barr PM, Pu JJ, Patten PE, Perini GF, Huntington SF, Parry H, Sundaram S, Skarbnik AP, Kamdar M, Jacobs RW, Walter HS, Walewska R, Broom A, Lebowitz S, Isaac K, Portell CA, Ahn IE, Ujjani C, Shadman M, Skånland SS, Chong EA, Mato AR
Blood
May 18, 2021Real-world treatment sequencing and healthcare costs among CLL/SLL patients treated with Venetoclax.
Rogers KA, Emond B, Manceur AM, Kinkead F, Lafeuille MH, Lefebvre P, Huang Q
Curr Med Res Opin
May 4, 2021Hairy cell leukemia and COVID-19 adaptation of treatment guidelines.
Grever M, Andritsos L, Banerji V, Barrientos JC, Bhat S, Blachly JS, Call T, Cross M, Dearden C, Demeter J, Dietrich S, Falini B, Forconi F, Gladstone DE, Gozzetti A, Iyengar S, Johnston JB, Juliusson G, Kraut E, Kreitman RJ, Lauria F, Lozanski G, Parikh SA, Park J, Polliack A, Ravandi F, Robak T, Rogers KA, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam CS, Tiacci E, Troussard X, Zent C, Zenz T, Zinzani PL, Wörmann B
Leukemia
April 5, 2021Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients.
Miller CR, Huang Y, Ruppert AS, Labanowska J, Jaglowski SM, Maddocks KJ, Rogers KA, Bhat S, Kittai AS, Grever M, Lapalombella R, Abruzzo LV, Heerema NA, Byrd JC, Hertlein EK, Woyach JA
Leukemia
March 22, 2021Phase 2 Study of Ibrutinib in Classic and Variant Hairy Cell Leukemia.
Rogers KA, Andritsos LA, Wei L, McLaughlin E, Ruppert AS, Anghelina M, Blachly JS, Call TG, Chihara D, Dauki AM, Guo L, Ivy SP, James L, Jones D, Kreitman RJ, Lozanski G, Lucas DM, Ngankeu A, Phelps MA, Ravandi F, Schiffer C, Carson Iii WE, Jones JA, Grever MR
Blood
March 18, 2021Phase 2 study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia.
Rogers KA, Thompson PA, Allan JN, Coleman M, Sharman JP, Cheson BD, Jones D, Izumi R, Frigault MM, Quah C, Raman RK, Patel P, Wang MH, Kipps TJ
Haematologica
January 15, 2021Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia.
Walker JS, Hing ZA, Harrington B, Baumhardt J, Ozer HG, Lehman A, Giacopelli B, Beaver L, Williams K, Skinner JN, Cempre CB, Sun Q, Shacham S, Stromberg BR, Summers MK, Abruzzo LV, Rassenti L, Kipps TJ, Parikh S, Kay NE, Rogers KA, Woyach JA, Coppola V, Chook YM, Oakes C, Byrd JC, Lapalombella R
J Hematol Oncol
December 1, 2020Second cancer incidence in CLL patients receiving BTK inhibitors.
Bond DA, Huang Y, Fisher JL, Ruppert AS, Owen DH, Bertino EM, Rogers KA, Bhat SA, Grever MR, Jaglowski SM, Maddocks KJ, Byrd JC, Woyach JA
Leukemia
November 19, 2020Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia.
Khountham S, Shindiapina P, Mo X, Lachowiez C, Wiczer T, Mousa L, Rogers KA, Andritsos LA, Woyach JA, Byrd JC, Spurgeon SE, Awan FT
Leuk Lymphoma
October 22, 2020Antiemetic medication efficacy during EPOCH and R-EPOCH treatment.
Fleming MK, Carr A, Li J, Lundberg JD, Rogers KA
J Oncol Pharm Pract
October 13, 2020Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome.
Kittai AS, Bond DA, William B, Saad A, Penza S, Efebera Y, Larkin K, Wall SA, Choe HK, Bhatnagar B, Vasu S, Brammer J, Shindiapina P, Long M, Mims A, O'Donnell L, Bhat SA, Rogers KA, Woyach JA, Byrd JC, Jaglowski SM
Blood Adv
October 13, 2020Safety of venetoclax rapid dose escalation in CLL patients previously treated with B-cell receptor signaling antagonists.
Koenig KL, Huang Y, Dotson EK, Sheredy S, Bhat SA, Byrd JC, Desmond E, Ford J, Iarocci S, Jones JA, Lucas MS, Moran ME, Wiczer TE, Woyach JA, Awan FT, Rogers KA
Blood Adv
October 5, 2020Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration.
Stephens DM, Boucher K, Kander E, Parikh SA, Parry EM, Shadman M, Pagel JM, Cooperrider J, Rhodes J, Mato A, Winter A, Hill B, Gaballa S, Danilov A, Phillips T, Brander DM, Smith SM, Davids M, Rogers K, Glenn MJ, Byrd JC
Haematologica
September 21, 2020Early intervention with lenalidomide in patients with high-risk chronic lymphocytic leukemia.
Thangavadivel S, Zhao Q, Epperla N, Rike LA, Mo X, Badawi M, Bystry D, Phelps MA, Andritsos L, Rogers KA, Jones J, Woyach JA, Byrd JC, Awan FT
Clin Cancer Res
August 14, 2020Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia.
Rogers KA, Huang Y, Ruppert AS, Abruzzo LV, Andersen BL, Awan FT, Bhat SA, Dean A, Lucas M, Banks C, Grantier C, Heerema NA, Lozanski G, Maddocks KJ, Valentine TR, Weiss DM, Jones JA, Woyach JA, Byrd JC
J Clin Oncol
June 18, 2020LC-FACSeq is a method for detecting rare clones in leukemia.
Hu EY, Blachly JS, Saygin C, Ozer HG, Workman SE, Lozanski A, Doong TJ, Chiang CL, Bhat S, Rogers KA, Woyach JA, Coombes KR, Jones D, Muthusamy N, Lozanski G, Byrd JC
JCI Insight
May 4, 2020Collectively Answering The Venetoclax BTK Inhibitor Sequencing Question in CLL.
Rogers KA
Clin Cancer Res
March 24, 2020Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations.
Lucas F, Larkin K, Gregory CT, Orwick S, Doong TJ, Lozanski A, Lozanski G, Misra S, Ngankeu A, Ozer HG, Sampath D, Thangavadivel S, Yilmaz AS, Rogers KA, Byrd J, Woyach JA, Blachly JS
Blood
Consulting and Related Relationships
More info forAt The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 09/30/2024, Dr. Rogers has reported relationships with the companies or entities listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office.
- AstraZeneca
- Genentech
- Pharmacyclics
- BeiGene, Ltd.
- AbbVie
- Janssen Pharmaceuticals
- Alpine Immunosciences
- Loxo@Lilly
Patient Comments
Dr Rogers and her team do a great job give me the attention needed and answering questions. I am very satisfied with their care.
Excellent experience
Dr Rogers always gives me quality time with her. She treats me as if I am her only patient that day. It is a comforting feeling to know she cares!
Dr. Rogers is very kind and knowledgeable and always answers all of my questions.
Dr Rogers and her staff are simply the best. She always takes time to review my blood numbers, discuss current treatment and future treatment options. I can't say enough good things about the whole team.
I cannot say enough about Dr Rogers. She spent a lot of time with me and my husband, explaining the diagnosis, treatment options, my condition and how it affects me personally, and did it in a way that we totally understood. She answered all of our questions and was so pleasant. My husband and I both left feeling confident about our treatment decision, and we were so thankful that we got a second opinion from Dr Rogers.
Awesome
Did not feel rushed. Dr took her time with me.
The nurse practicioner was well informed of all my health concerns
Kerry Rodgers is very personable and explains things in a way I can understand.
Dr Rogers is very generous with her time. She is extremely knowledgeable, and empathetic.
Dr. Kerry Rogers is great, personable, extremely knowledgeable as a physician scientist and she has made me feel very comfortable at The James. I would highly recommend her to others.
I am very grateful to have Dr. Rogers overseeing my care.
Super-wonderful in every way.
Excellent care
My doctor is fantastic and I have complete faith in her
Appreciate time spent answering my questions and concerns.
Dr. Rogers is the best!!!
Take the time to be concerned and friendly.
I'm grateful to have Dr. Rogers as my physician.
Top of the line
She always explains what she is seeing and answers any questions I have. And friendly too!!
Very pleased with my oncologist
Dr. Rogers is outstanding. She spent so much time with me to make sure I understood everything. She is brilliant, kind, compassionate, funny. This is the third time I have seen her and every time I leave feeling good and confident.
Dr Rogers is a great listener and generous with her time spent with me. Dr Rogers answers all my questions.
Dr. Rogers is amazing! She is extremely knowledgeable, professional, innovative, reassuring, and kind. She has a great sense of humor that she uses skillfully to put patients at ease even while she is discussing extremely serious medical issues with them. She is uncommonly compassionate and supportive. Any leukemia patient would be very fortunate to be treated by her.
Great experience!
We did not feel rushed at all. They encouraged us to ask questions. They were very thoughtful. Thorough. Explained everything very well. We felt like people. We were heard. They listened.
I am happy to have Dr. Kerry Rogers as my oncologist and I feel comfortable there.
Dr Kerry Rogers was very professional, informative. She took her time with my wife and me while answering all of our questions and listened to our concerns. The meeting left us very satisfied that we had gained more information than we had even hoped for.
Dr always answers any questions that I have as well as any that come up during our visit and diagnosis.
Dr Kerry Rogers is to be commended for her exceptional care of he patients.
Everyone that I saw was incredible. Very caring and I never feel rushed.
We were thoroughly explained how call works. All questions were answered. We have never been treated this well. I'm a huge fan
Outstanding!
Dr. Roger's and Staff are excellent
Dr Rogers and staff explained everything in detail and answered all of our questions.
Dr. Rogers is caring and takes time to answer questions and gives explanations.
They are just wonderful. I feel as if I am getting excellent care.
Dr Kerry Rogers is very compassionate, listens about any concerns, and goes over options of different kinds of treatments. She also works with my oncologist near my home about chemo treatments and the best strategy for me.
Dr Rogers is awesome. She answers all my questions. Dr Rogers is professional, knowledgeable and compassionate.
Best service by Dr. Kerry, the PA, and nurses. I have full confidence in my doctor.
Dr. Rodgers is an super with answering any questions we have. We feel so blessed to have her as my oncologist. They are all so kind and great to deal with at this facility!
Dr. Rogers is outstanding about answering all of my questions. She goes above and beyond In explaining her recommended treatment plan.
Dr Rogers and her staff are professional and caring. My initial treatment was with Dr. Byrd and when he left, she accepted me as her patient in the trial.